As of November 6, 2026, DarioHealth Corp. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 13, 2026 to September 4, 2026, naming 1 appointment and 1 departure. The latest filing names Lawrence Leisure, leaving (Form 8-K, September 4, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like DarioHealth Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
DarioHealth Corp. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-13 to 2026-09-04. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as DarioHealth Corp. files it.
Also on the record for DarioHealth Corp.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 13, 2026 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 9.99% of the class | 5%+ stakes | Source |
| December 16, 2025 | Stake report, Schedule 13G, by Craig Kallman 2015 Living Trust | 9.99% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 9.99% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP | 4.5912% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G/A, by Tasso Partners, LLC | 9.99% of the class | 5%+ stakes | Source |
| October 9, 2025 | Stake report, Schedule 13G/A, by Titan Trust 2024 I | — | 5%+ stakes | Source |
| October 7, 2025 | Form D, private offering | $17.50M sold | Form D page | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 9.99% of the class | 5%+ stakes | Source |
| July 22, 2025 | Stake report, Schedule 13G, by Titan Trust 2024 I | 5.32% of the class | 5%+ stakes | Source |
| July 18, 2025 | Stake report, Schedule 13G/A, by Titan Trust 2024 I | — | 5%+ stakes | Source |
| January 17, 2025 | Form D, private offering | $18.80M sold | Form D page | Source |
| January 17, 2025 | Form D, private offering | $6.80M sold | Form D page | Source |
Selling to them or working with them? See who runs DarioHealth Corp. now and the warning signs.
Free to see. No signup.
Keep reading
More on DarioHealth Corp. and the records around it.
The people at DarioHealth Corp.
- Dennis McGrath is also named on 12 other Form D filings: PAVmed Inc. (Feb 2026), Veris Health Inc. (Jul 2025)
- Hila Karah is also named on 9 other Form D filings: Indaptus Therapeutics, Inc. (Jun 2025)
DarioHealth Corp. elsewhere on the record
- 5%+ stake filings Feb 2026
- Form D filing Oct 2025
- Who owns it
Companies that share a holder
- Craig Kallman 2015 Living Trust also filed stake reports on 1 other company: PAVmed Inc. (Oct 2026)
- Tasso Partners, LLC also filed stake reports on 2 other companies: PAVmed Inc. (Apr 2026), Orchestra BioMed Holdings, Inc. (Nov 2025)
- NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP also filed stake reports on 6 other companies: FEMASYS INC. (Aug 2026), AZITRA, INC. (Aug 2026), ABEONA THERAPEUTICS INC. (May 2026)
Watch DarioHealth Corp.
Get an email when DarioHealth Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on DarioHealth Corp.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on DarioHealth Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on DarioHealth Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-04 | Out | 2026-09-02 | 8-K, 2026-09-04 | ||
| 2026-04-13 | In | Director | 8-K, 2026-04-13 |
Who leads DarioHealth Corp., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: John R. Palumbo, appointed (filed 2026-04-13).
New leaders reset buying decisions — get the Full Report on DarioHealth Corp.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at DarioHealth Corp., with the record behind each one.
Find candidates like Director at DarioHealth Corp.Every change, in the filing's words
Departing: Lawrence Leisure, effective 2026-09-02
On September 2, 2026, Lawrence Leisure notified the Board of Directors (the "Board") of DarioHealth Corp. (the "Company") of his decision to retire from the Board, effective September 2, 2026, for personal reasons.
- Mr. Leisure's decision to retire was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Appointed: John R. Palumbo, Director
Appointment of John R. Palumbo to Board of Directors On April 10, 2026, on the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors, or the Board, of DarioHealth Corp., or the Company, the Board appointed John R. Palumbo as a member of the Board, effective immediately.
- Mr. Palumbo, 75, brings more than 40 years of healthcare operating experience across early-stage ventures and Fortune 100 enterprises, guiding organizations through transformative growth, including supporting two companies through IPOs and leading large-scale operational and commercial transformations.
- Since August 2023, Mr. Palumbo has served on the Board of Directors, and the audit and compensation committees, of PM Pediatrics Management Group, LLC, a specialized urgent care provider that offers comprehensive, evidence-based medical and mental health services for children and young adults from birth through age 26.
- Since September 2025, Mr. Palumbo has served on the Board of Directors, and the audit and compensation committees, of Lucid Diagnotics Inc. (NASDAQ: LUCD), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM).
- Since May 2025, Mr. Palumbo has served on the Board of Directors of ivWatch, LLC, a medical device company that develops and manufactures the world's only FDA-cleared and CE-marked biosensor technology designed to continuously monitor peripheral IV sites for early detection of infiltration and extravasation events.
Tools for this story
Each opens in a new tab, filled in for DarioHealth Corp.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.